Using multi-omics methods to understand dermatomyositis/polymyositis

Siming Gao; Hui Luo; Huali Zhang; Xiaoxia Zuo; Li Wang; Honglin Zhu

doi:10.1016/j.autrev.2017.07.021

Using multi-omics methods to understand dermatomyositis/polymyositis

Autoimmun Rev. 2017 Oct;16(10):1044-1048. doi: 10.1016/j.autrev.2017.07.021. Epub 2017 Aug 1.

Authors

Siming Gao¹, Hui Luo¹, Huali Zhang², Xiaoxia Zuo¹, Li Wang², Honglin Zhu³

Affiliations

¹ Department of Rheumatology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan 410008, People's Republic of China.
² Department of Pathophysiology, Xiangya School of Medicine, Central South University, 110 Xiangya Road, Changsha, Hunan 410008, People's Republic of China.
³ Department of Rheumatology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan 410008, People's Republic of China. Electronic address: zhuhonglin1988@hotmail.com.

PMID: 28778709
DOI: 10.1016/j.autrev.2017.07.021

Abstract

Idiopathic inflammatory myopathies (IIM) are a group of rare and heterogeneous autoimmune diseases, and the most common subtypes are dermatomyositis (DM) and polymyositis (PM). Despite extensive efforts, the underlying mechanism of IIM remains unclear. Recent efforts to understand the pathogenesis of IIM have included genomics, epigenetics, transcriptomics, proteomics and autoantibody studies. This review focuses on recent studies in DM/PM research based on multi-omics. This integrated analysis of multi-omics profiling will provide useful insights into DM/PM pathogenesis and recommendations for therapeutic targets and biomarkers development.

Keywords: Dermatomyositis; Multi-omics; Pathogenesis; Polymyositis.

Publication types

Review

MeSH terms

Dermatomyositis / pathology
Dermatomyositis / therapy*
Humans
Metabolomics*
Polymyositis / pathology
Polymyositis / therapy*